Leerink Swann Positive on NxStage Medical (NXTM) After Aetna (AET) Update Adds Confirmation
Tweet
Share
E-mailGet Alerts NXTM Hot Sheet
Price: $30.00 --0%
Rating Summary:
5 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann maintains an 'Outperform' on NxStage Medical (NASDAQ: NXTM) price target of $25.00.
Analyst, Danielle Antalffy, said, "On 6/15, Aetna (NYSE: AET)(Outperform) released its policy update supporting home hemodialysis with NXTM's System One machine as "medically necessary" vs. its prior designation as "experimental". We view this change positively for NXTM as: 1) it is another step closer to establishing routine care, in line with UnitedHealth's (NYSE: UNH)(Market Perform) policy update earlier this year and 2) it could potentially serve as further evidence supporting possible improvements in home hemodialysis reimbursement from CMS. With NXTM shares trading nearly 30% off YTD highs despite no real change to fundamentals, we believe current levels offer an attractive entry point. Investors seem to be searching for an inflection point in home hemo adoption, which is difficult to predict."
For an analyst ratings summary and ratings history on NxStage Medical click here. For more ratings news on NxStage Medical click here.
Shares of NxStage Medical closed at $15.62 yesterday.
Analyst, Danielle Antalffy, said, "On 6/15, Aetna (NYSE: AET)(Outperform) released its policy update supporting home hemodialysis with NXTM's System One machine as "medically necessary" vs. its prior designation as "experimental". We view this change positively for NXTM as: 1) it is another step closer to establishing routine care, in line with UnitedHealth's (NYSE: UNH)(Market Perform) policy update earlier this year and 2) it could potentially serve as further evidence supporting possible improvements in home hemodialysis reimbursement from CMS. With NXTM shares trading nearly 30% off YTD highs despite no real change to fundamentals, we believe current levels offer an attractive entry point. Investors seem to be searching for an inflection point in home hemo adoption, which is difficult to predict."
For an analyst ratings summary and ratings history on NxStage Medical click here. For more ratings news on NxStage Medical click here.
Shares of NxStage Medical closed at $15.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- New Street Research Upgrades Micron Technology (MU) to Buy
- DA Davidson Reiterates Neutral Rating on Timken (TKR)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
